It was shown that for the whole population of patients with BRAF V600-mutated melanoma there was no statistically significant OS benefit of adjuvant TT versus placebo (hazard ratio (HR) for death, 0.80; 95 % confidence interval [CI], 0.62 to 1.01; p = 0.06). This evidence concerns the gene BRAF and melanoma.